Biochemical Prediction of Response in Bone Metastases Treatment
Author Information
Author(s): R.E. Coleman, K.B. Whitaker, D.W. Moss, G. Mashiter, I. Fogelman, R.D. Rubens
Primary Institution: Imperial Cancer Research Fund Clinical Oncology Unit, Guy's Hospital
Hypothesis
Can biochemical markers predict the response of bone metastases to systemic therapy in breast cancer patients?
Conclusion
Biochemical monitoring can reliably predict the response of bone metastases to treatment before radiological changes are visible.
Supporting Evidence
- 14 out of 16 patients with radiographic evidence of bone healing showed significant biochemical changes after treatment.
- Only 4 out of 20 patients with progressive disease showed similar biochemical changes.
- The combination of biochemical markers had a diagnostic efficiency of 89% for discriminating response from progression.
Takeaway
Doctors can use blood tests to see if treatment for bone cancer is working, even before X-rays show any changes.
Methodology
A prospective study measuring biochemical markers and correlating them with radiological responses in breast cancer patients with bone metastases.
Limitations
The study's conclusions are based on retrospective analysis and require independent confirmation.
Participant Demographics
Seventy women with advanced breast cancer and progressing bone metastases, median age 58 (range 32-82 years).
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website